Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
21,250
-200 (-0.93%)
Jun 27, 2025, 3:30 PM KST

Onconic Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
22,68814,83821,0569560
Revenue Growth (YoY)
80.79%-29.53%22064.25%58.33%-
Cost of Revenue
3.733.782.3714,9338,402
Gross Profit
22,68414,83521,054-14,838-8,342
Selling, General & Admin
12,1268,0872,463--
Research & Development
10,17110,92915,761--
Other Operating Expenses
120.47164.15138.3--
Operating Expenses
22,87719,63218,823--
Operating Income
-192.43-4,7982,231-14,838-8,342
Interest Expense
-174.05-664.16-1,776-1,078-6,831
Interest & Investment Income
1,162942.63863.011,43118.85
Currency Exchange Gain (Loss)
1,5082,020-79.65--
Other Non Operating Income (Expenses)
-7,445-7,442-576.0952.865.74
EBT Excluding Unusual Items
-5,141-9,942662.51-14,432-15,149
Gain (Loss) on Sale of Assets
---0.7--
Pretax Income
-5,141-9,942661.81-14,432-15,149
Income Tax Expense
-1,980-1,849-1,021--
Net Income
-3,162-8,0931,682-14,432-15,149
Net Income to Common
-3,162-8,0931,682-14,432-15,149
Shares Outstanding (Basic)
118111
Shares Outstanding (Diluted)
118111
Shares Change (YoY)
-1314.60%-0.00%0.94%-
EPS (Basic)
-291.84-989.812911.00-24969.04-26456.01
EPS (Diluted)
-291.84-989.812911.00-24969.04-26456.01
Free Cash Flow
-4,557-7,9822,983-17,536-8,861
Free Cash Flow Per Share
-420.68-976.305160.40-30339.54-15475.92
Gross Margin
99.98%99.98%99.99%--
Operating Margin
-0.85%-32.33%10.60%-15618.48%-13903.24%
Profit Margin
-13.94%-54.54%7.99%-15191.48%-25247.72%
Free Cash Flow Margin
-20.09%-53.79%14.16%-18458.96%-14769.11%
EBITDA
258.38-4,3452,691-14,770-8,292
EBITDA Margin
1.14%-29.28%12.78%--
D&A For EBITDA
450.81452.67460.1367.4349.65
EBIT
-192.43-4,7982,231-14,838-8,342
EBIT Margin
-0.85%-32.33%10.60%--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.